Dorfman D M, Kraus M, Perez-Atayde A R, Barnhill R L, Pinkus G S, Granter S R
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Mod Pathol. 1997 Apr;10(4):283-8.
The diagnosis of leukemia cutis and distinction of early myeloid cells and blasts from lymphoblasts or other lymphoid cells can be difficult, particularly if only fixed tissue is available. O13, a monoclonal antibody that recognizes CD99, the p30/32MIC2 gene product, has been used to identify a number of cell types, including lymphoblasts, in paraffin sections. To evaluate the usefulness of CD99 immunoreactivity in the diagnosis of leukemia cutis, we analyzed cases of cutaneous involvement by acute lymphoblastic leukemia/lymphoblastic lymphoma and acute myelogenous leukemia for the presence of this marker. Without the use of antigen retrieval methods, lymphoblasts in cases of cutaneous involvement by acute lymphoblastic leukemia/lymphoblastic lymphoma were immunoreactive for CD99 in 9 of 9 cases. Myeloblasts and early myeloid cells in cases of cutaneous involvement by acute myelogenous leukemia were immunoreactive for CD99 in 12 (80%) of 15 cases. We conclude that CD99 is a sensitive but nonspecific marker for cutaneous involvement by acute lymphoblastic leukemia/lymphoblastic lymphoma and that CD99 is immunoreactive in the vast majority of cases (21 [88%] of 24 cases) of leukemia cutis.
皮肤白血病的诊断以及早期髓样细胞和原始细胞与淋巴母细胞或其他淋巴细胞的区分可能存在困难，特别是在仅能获得固定组织的情况下。O13是一种识别CD99（p30/32MIC2基因产物）的单克隆抗体，已被用于在石蜡切片中识别多种细胞类型，包括淋巴母细胞。为了评估CD99免疫反应性在皮肤白血病诊断中的实用性，我们分析了急性淋巴细胞白血病/淋巴母细胞淋巴瘤和急性髓性白血病皮肤受累病例中该标志物的存在情况。在未使用抗原修复方法的情况下，急性淋巴细胞白血病/淋巴母细胞淋巴瘤皮肤受累病例中的9例淋巴母细胞对CD99呈免疫反应性。急性髓性白血病皮肤受累病例中的15例中有12例（80%）原始粒细胞和早期髓样细胞对CD99呈免疫反应性。我们得出结论，CD99是急性淋巴细胞白血病/淋巴母细胞淋巴瘤皮肤受累的敏感但非特异性标志物，并且在绝大多数（24例中的21例[88%]）皮肤白血病病例中CD99呈免疫反应性。
